Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Elsewhere, medical diagnostics provider Angle jumped 28% after it said it has signed a supplier agreement with FTSE 100-listed pharmaceutical firm AstraZeneca.
The AIM listing explained that the contract is to develop and validate a methodology leveraging Angle's existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.
Chief Executive Andrew Newland commented: "This is Angle's second large pharma company agreement of 2024 as we look to drive a significant expansion of the pharma services business. It demonstrates the importance of CTC analysis and is a validation of Angle's Parsortix system. Angle is also working to expand its DDR work with other large pharma customers and continues to generate significant new customer interest through its business development activity."
Https://www.lse.co.uk/ShareBrokerTips.html?shareprice=AGL&share=Angle
Broker Rating 70p
Amala Foods Plc
("Amala" or the "Company")
Transaction Update
Amala Foods Plc (LON: DISH) is pleased to announce a further update following the Temporary Suspension of its listing on the Standard Segment of the Official List of the Main Market that was first announced on 9 November 2023 and subsequently on 4 January 2024.
The Company is pleased to update the market that the announced transaction continues to progress. The Company has made further prospectus submissions to the Financial Conduct Authority (FCA) and anticipates its next submission within the coming weeks once the audited numbers of the target company are available.
As previously announced the target company is a newly formed healthcare group, Healthcare Medical Plus Pte Ltd with a Philippine subsidiary, Dialysis Care Plus Inc, which is building dialysis centres in the Philippines where the market for dialysis services is growing substantially every year. The group continues to grow and has executed agreements to acquire, prior to Admission, of a diagnostic centre, that has a multiyear positive track record. In addition, the group has formed a new subsidiary, VidaHealth Inc which has funded a new diagnostic clinic where it has a 70% interest and has an Option to build a further 50 diagnostic centres.
The Directors are targeting that the transaction will be concluded in the summer of 2024 and the Directors will provide further updates to the market in due course.
Whilst the Directors are confident that a successful transaction will result in a Reverse Takeover, subject to regulatory approval, there can be no guarantee of such.